category,datetime,headline,id,image,related,source,summary,url
company,1769104917,BMS bets on Janux’s novel solid tumour therapy through $850m deal,138206964,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,BMY,Yahoo,"This deal marks another addition to BMS’s growing pipeline, which the company hopes will stave off the impacts of the upcoming patent cliff.",https://finnhub.io/api/news?id=440d0eb1b8026e31a7f55da47f7c823276e7c02f6e795c530db9f9b3dafbccdb
company,1769091300,Is BMY's Deep Pipeline the Key to Its Next Growth Phase?,138205782,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,BMY,Yahoo,"BMY spotlights a deep pipeline with multi-billion-dollar potential, key late-stage data readouts ahead, and encouraging uptake of the new schizophrenia drug Cobenfy.",https://finnhub.io/api/news?id=e30052199250baef2f56947ed670fb7e5683f6ed6f976ba74c3672c512b334a9
company,1769083200,Bristol Myers buys into Janux’s ‘masked’ T cell engagers,138205930,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,BMY,Yahoo,"Worth up to $850 million, the partnership provides “further validation” for Janux at a time of heightened investor scrutiny regarding the potential of its top drug, one analyst wrote.",https://finnhub.io/api/news?id=14a72ccaef9d0511c7e1875a55c4c505cf2ceda8ffc76119c8808f7ec9b2c04f
company,1769083200,Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer,138203770,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,BMY,Yahoo,"Joint initiative to focus on expanding early detection and equitable access to care through lung cancer specific AI workflows on Microsoft's suite of radiology solutions Originally published on BMS.com PRINCETON, NJ / ACCESS Newswire / January 22, ...",https://finnhub.io/api/news?id=17aecebff34662793875a01f08d5f4dbf83cb73f5bf9a6f8849b8489449a3b34
company,1769083200,Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors,138203909,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,BMY,Yahoo,"SAN DIEGO, January 22, 2026--Janux Therapeutics, Inc. (Nasdaq: JANX) (""Janux""), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb. Under the terms of the agreement, th",https://finnhub.io/api/news?id=8c08c0832f04894d8472a356961ba5f28b51fcc3dd8a88ff21c2167a02c7da6a
company,1769067180,Janux Shares Rise On Solid Tumor License Agreement with Bristol Myers Squibb,138210474,,BMY,MarketWatch,Janux Shares Rise On Solid Tumor License Agreement with Bristol Myers Squibb,https://finnhub.io/api/news?id=4a1c5cbb56bcfbf87f266ed6fa67d13f280847b9f18f5d102bca635bb9f40bcb
company,1769058000,Top 10 Dividend Stocks For Uncertain Times,138202582,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2217841231/image_2217841231.jpg?io=getty-c-w1536,BMY,SeekingAlpha,"Investors seeking stability amid market volatility, dividend stocks, including REITs, can offer a steady income. Discover Top 10 Dividend Stocks For 2026.",https://finnhub.io/api/news?id=6e8dbfc6b94d196c64a62677b4bffe7289b7fff5959c871a41bd72e980d2bbcb
company,1769050023,Bristol-Myers (BMY): UBS Turns Bullish as Biotech and Pharma Show Signs of a Recovery,138200779,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,BMY,Yahoo,"Bristol-Myers Squibb Company (NYSE:BMY) is included among the 15 Best High Yield Stocks to Buy. On January 7, UBS upgraded Bristol-Myers Squibb Company (NYSE:BMY) to a Buy from Neutral. The firm lifted its price target sharply to $65, from $46. UBS said the biotech and pharma space looks like it’s finally turning a corner after […]",https://finnhub.io/api/news?id=c1fa1c3846f594d4790179d317d9e538cf88978f2f45cf3d361b2db06f7ce615
